# Run 7 R7.1/R7.2 real HTTP/external eval — clinician failure digest

Artifact: `docs/eval/run7_real_external_20260725_220026.json`
Created: 2026-07-25T22:00:26+00:00
SUT: `gate-v2-gpt-5-mini`
External judge: `gpt-5`

Scorecard: **4 PASS / 12 MINOR / 16 FAIL**; routing 100.0%; verbatim 100.0%. Delta vs Run 6 (**4/13/15**): **PASS ±0 / MINOR -1 / FAIL +1**.

> This is an inspectable strict-judge result for clinician calibration, not an authoritative clinical pass/fail verdict. `no_grade_drop` still compares against fixture-derived grades and is not meaningful.

> The default process-concurrency HTTP run aborted at F4 after 24/32 turns because Laravel's child-process pool hit its fixed 60-second timeout. This complete quality run used `GATE_V2_CONCURRENCY_DRIVER=sync` in the disposable SUT server only. No production/default config changed. Timing from this run is excluded; the committed default-driver latency artifact is authoritative for performance.

> Chunk counts sum `snippet_count` across retrieval trace entries, including guideline branches and retries. Zero identifies retrieval starvation; non-zero distinguishes retrieval transport from reasoning/coverage failures.

## Per-case overview

| Scenario | Turn | Grade | Coverage | Expected routes | Routed routes | Retrieval chunks |
|---|---:|---|---|---|---|---:|
| aaa_evolving_context | 1 | PASS | covered | abdominal_aortic_aneurysm | abdominal_aortic_aneurysm | 18 |
| aaa_evolving_context | 2 | FAIL | interaction_gap | abdominal_aortic_aneurysm | abdominal_aortic_aneurysm | 13 |
| aaa_evolving_context | 3 | FAIL | covered | abdominal_aortic_aneurysm | abdominal_aortic_aneurysm | 20 |
| adversarial_case_switch_chimera | 1 | PASS_WITH_MINOR | covered | carotid_vertebral | carotid_vertebral | 10 |
| adversarial_case_switch_chimera | 2 | FAIL | interaction_gap | carotid_vertebral | carotid_vertebral | 11 |
| adversarial_case_switch_chimera | 3 | PASS | interaction_gap | abdominal_aortic_aneurysm | abdominal_aortic_aneurysm, carotid_vertebral | 20 |
| adversarial_correction_flip | 1 | PASS | covered | carotid_vertebral | carotid_vertebral | 6 |
| adversarial_correction_flip | 2 | FAIL | interaction_gap | carotid_vertebral | carotid_vertebral | 16 |
| adversarial_declined_question_persistence | 1 | FAIL | covered | asymptomatic_pad | asymptomatic_pad | 12 |
| adversarial_declined_question_persistence | 2 | PASS_WITH_MINOR | interaction_gap | asymptomatic_pad | asymptomatic_pad | 20 |
| adversarial_declined_question_persistence | 3 | FAIL | interaction_gap | asymptomatic_pad | asymptomatic_pad | 14 |
| adversarial_duplicate_delivery | 1 | FAIL | covered | abdominal_aortic_aneurysm | abdominal_aortic_aneurysm | 20 |
| adversarial_duplicate_delivery | 2 | FAIL | covered | abdominal_aortic_aneurysm | abdominal_aortic_aneurysm | 10 |
| adversarial_knowledge_interleave | 1 | FAIL | partial_principles | abdominal_aortic_aneurysm | abdominal_aortic_aneurysm | 8 |
| adversarial_knowledge_interleave | 2 | FAIL | covered | abdominal_aortic_aneurysm | abdominal_aortic_aneurysm | 6 |
| adversarial_knowledge_interleave | 3 | FAIL | covered | abdominal_aortic_aneurysm | abdominal_aortic_aneurysm | 6 |
| adversarial_retrieval_trap | 1 | FAIL | partial_principles | abdominal_aortic_aneurysm | abdominal_aortic_aneurysm | 18 |
| batch_c1_proximal_dvt_simple | 1 | PASS_WITH_MINOR | covered | venous_thrombosis | venous_thrombosis, antithrombotic_therapy | 20 |
| batch_c2_brachial_vein_compression | 1 | PASS_WITH_MINOR | not_covered | venous_thrombosis | venous_thrombosis, antithrombotic_therapy | 51 |
| batch_c3_carotid_near_occlusion_criteria | 1 | PASS_WITH_MINOR | not_covered | carotid_vertebral | carotid_vertebral | 7 |
| batch_f1_clti_aps_warfarin | 1 | PASS_WITH_MINOR | interaction_gap | clti, antithrombotic_therapy | clti, antithrombotic_therapy | 32 |
| batch_f2_clti_itp_after_bypass | 1 | FAIL | not_covered | clti, antithrombotic_therapy | clti, antithrombotic_therapy | 11 |
| batch_f3_aaa_clti_sequencing | 1 | PASS_WITH_MINOR | not_covered | abdominal_aortic_aneurysm, clti | abdominal_aortic_aneurysm, clti | 58 |
| batch_f4_aaa_clti_sepsis_anticoagulation | 1 | PASS_WITH_MINOR | not_covered | abdominal_aortic_aneurysm, clti, antithrombotic_therapy | abdominal_aortic_aneurysm, clti, antithrombotic_therapy | 26 |
| batch_f5_urgent_cea_af_recent_gi_bleed | 1 | FAIL | interaction_gap | carotid_vertebral, antithrombotic_therapy | carotid_vertebral, antithrombotic_therapy | 45 |
| batch_f6_aps_clti_bypass_vs_amputation | 1 | PASS | interaction_gap | clti, antithrombotic_therapy | clti, antithrombotic_therapy | 44 |
| batch_s1_asymptomatic_carotid_stenosis | 1 | PASS_WITH_MINOR | interaction_gap | carotid_vertebral | carotid_vertebral | 24 |
| batch_s2_post_vein_bypass_antithrombotics | 1 | FAIL | interaction_gap | clti, antithrombotic_therapy | clti, antithrombotic_therapy | 19 |
| batch_s3_post_endovascular_antithrombotics_itp | 1 | PASS_WITH_MINOR | interaction_gap | clti, antithrombotic_therapy | clti, antithrombotic_therapy | 39 |
| batch_s4_symptomatic_carotid_web | 1 | PASS_WITH_MINOR | interaction_gap | carotid_vertebral | carotid_vertebral | 19 |
| batch_s5_iliofemoral_dvt_recent_surgery | 1 | PASS_WITH_MINOR | interaction_gap | venous_thrombosis | venous_thrombosis, antithrombotic_therapy | 11 |
| batch_s6_urgent_cea_af_apixaban | 1 | FAIL | interaction_gap | carotid_vertebral, antithrombotic_therapy | carotid_vertebral, antithrombotic_therapy | 47 |

## MINOR / FAIL details

### aaa_evolving_context — turn 2 — FAIL

- Scenario turn: CTA now shows that this is a juxtarenal aneurysm with an inadequate infrarenal neck for standard EVAR. His eGFR is 28 mL/min/1.73 m². How does this change your recommendation?
- Expected guidelines: abdominal_aortic_aneurysm
- Routed guidelines: abdominal_aortic_aneurysm
- Evidence coverage: `interaction_gap`
- Retrieval returned 13 chunks: **YES**
- Judge labels: `MISSING_REQUIRED_FACTS`
- Judge reason: The response omitted multiple must-include facts: the patient’s age, aneurysm size and asymptomatic status, active smoking, hypertension, dyslipidaemia, explicit fitness assessment, and explicit contrast-nephropathy caution. While it covered juxtarenal anatomy, inadequate neck, EVAR unsuitability, FEVAR/open options, and eGFR, the several missing required elements warrant failure.

#### `guideline_grounded_answer` (verbatim)

~~~~text
The ESVS guidelines for abdominal aortic aneurysm do not provide a recommendation that specifically addresses the optimal management for juxtarenal AAA with inadequate infrarenal neck in the context of significant renal impairment (eGFR 28 mL/min/1.73 m²). In the context of endovascular thoraco-abdominal aortic repair, ESVS notes that 'fenestrations may be considered preferred over branches for the renal arteries when the endograft is adjacent to the aortic wall at the level of the renal arteries' (Class IIb, Level C), but this statement is not directly extended to juxtarenal abdominal aneurysm management.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
Although ESVS guidelines do not provide a unified recommendation for the interaction of juxtarenal anatomy and severe renal impairment, clinically, the combination of inadequate infrarenal neck and eGFR 28 mL/min/1.73 m² significantly complicates both open surgical and endovascular solutions. Fenestrated EVAR (fEVAR) is commonly considered when standard EVAR is not feasible due to neck anatomy; however, either complex EVAR or open repair in a patient with significant renal dysfunction is associated with a higher risk of worsening renal function and perioperative morbidity. In practice, the choice is individualized based on anatomy, local expertise, and patient preferences, and often involves a multidisciplinary assessment considering risks of dialysis. ESVS does not mandate or exclude any single approach in this context. Further risk–benefit deliberation and patient discussion are advised before definitive management.
~~~~

### aaa_evolving_context — turn 3 — FAIL

- Scenario turn: He also has severe COPD, reduced functional capacity, and significant frailty, but remains independent in basic daily activities. Should he still undergo repair, and how would you choose between open repair, FEVAR, and conservative management?
- Expected guidelines: abdominal_aortic_aneurysm
- Routed guidelines: abdominal_aortic_aneurysm
- Evidence coverage: `covered`
- Retrieval returned 20 chunks: **YES**
- Judge labels: `missing_required_facts`, `missing_anatomy_feasibility_context`, `missing_renal_function_consideration`, `incomplete_option_tradeoffs`
- Judge reason: The response omits multiple must-include case details (74-year-old, asymptomatic 5.8 cm AAA, active smoker, hypertension, dyslipidaemia), does not mention the juxtarenal anatomy or that standard EVAR is unsuitable, and fails to address the eGFR 28 mL/min/1.73 m² with contrast-nephropathy caution. It also does not explicitly compare open repair versus FEVAR versus conservative management as required, beyond generally recommending against intervention. Although it acknowledges severe COPD, frailty, reduced functional capacity, and independence in ADLs with a shared-decision note, it does not meet the specified must-include elements for this turn.

#### `guideline_grounded_answer` (verbatim)

~~~~text
According to ESVS guidelines, elective repair of an abdominal aortic aneurysm (AAA)—either open or endovascular—is not recommended in patients with limited life expectancy, severe comorbidities, significant frailty, or reduced functional capacity. The guideline specifically advises against intervention in such circumstances, regardless of whether endovascular or open approaches (including FEVAR) are considered. The recommendation that endovascular repair is preferred applies only to patients with suitable anatomy and reasonable life expectancy, which does not include those with severe frailty or significantly reduced fitness as in this case.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
In practice, the decision to avoid intervention in the presence of severe COPD and significant frailty aligns with the high perioperative risk and limited likelihood of functional recovery after repair. Independence in basic daily activities does not negate the impact of overall frailty and severely reduced functional capacity. If the patient's life expectancy is substantially limited by comorbidity and frailty, conservative management is usually the most appropriate approach. The only substantial reason to proceed to any form of repair would be a strong, well-informed patient preference and multidisciplinary consensus that benefit outweighs risk, which remains rare in this context.
~~~~

### adversarial_case_switch_chimera — turn 1 — PASS_WITH_MINOR

- Scenario turn: A 68-year-old woman had a TIA yesterday and has 75% left carotid stenosis. What should we do?
- Expected guidelines: carotid_vertebral
- Routed guidelines: carotid_vertebral
- Evidence coverage: `covered`
- Retrieval returned 10 chunks: **YES**
- Judge labels: `missing_required_facts`
- Judge reason: Meets mode and guideline focus, stays within question limits, and includes key clinical context (recent TIA, 75% symptomatic carotid stenosis, age 68). However, it omits two required explicit facts from the prompt: does not state the patient is a woman and does not specify the stenosis is on the left side.

#### `guideline_grounded_answer` (verbatim)

~~~~text
For a patient with symptomatic carotid stenosis (75%) and a recent TIA (yesterday), ESVS guidelines recommend carotid endarterectomy for those meeting criteria similar to this patient—recent symptoms (within 6 months) and moderate-to-severe stenosis (50-99%). The key referenced recommendation applies specifically to age ≥70, but similar principles likely apply to age slightly below 70, as in this 68-year-old. There is also a general statement that for symptomatic patients (reported symptoms in the preceding six months) and 70–99% carotid stenosis, carotid endarterectomy is recommended provided the 30-day death/stroke risk is acceptable.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
Although the definitive ESVS statement for CEA over stenting is anchored at age 70 and above, the risk-benefit rationale for carotid endarterectomy in symptomatic patients with 70–99% stenosis and recent TIA applies closely here. In the absence of major comorbidity or contraindications (not supplied), it is reasonable to proceed to early carotid endarterectomy for this 68-year-old. Decision may further be informed by perioperative risk assessment and multidisciplinary discussion as per ESVS principles, but the default course is timely CEA.
~~~~

### adversarial_case_switch_chimera — turn 2 — FAIL

- Scenario turn: She is functionally independent and the event was non-disabling.
- Expected guidelines: carotid_vertebral
- Routed guidelines: carotid_vertebral
- Evidence coverage: `interaction_gap`
- Retrieval returned 11 chunks: **YES**
- Judge labels: `missing_required_facts`, `evidence_status_mismatch`
- Judge reason: The response did not include several required case facts (age/sex 68-year-old woman, timing TIA yesterday, and left-sided stenosis), only mentioning functional independence, non-disabling event, and 75% stenosis in general. Additionally, the evidence status was presented as having an interaction gap, whereas the turn’s expected evidence coverage was marked as covered.

#### `guideline_grounded_answer` (verbatim)

~~~~text
According to ESVS guidelines, in functionally independent patients with recent non-disabling TIA and 75% symptomatic carotid stenosis, carotid intervention (endarterectomy or stenting) should be performed as soon as possible, preferably within 14 days of symptom onset. Carotid endarterectomy is recommended for most patients with 50–99% stenosis if they are considered appropriate candidates with acceptable perioperative risk (30-day risk of death/stroke <6%). Carotid stenting can be considered as an alternative in those with high surgical risk related to anatomy or medical comorbidities, again if predicted 30-day risk is <6%. No direct ESVS recommendation for best medical management alone is present for suitable surgical candidates.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
The main branching question not covered by the guideline text is surgical risk: If the patient has significant comorbidity, anatomical issues, or contraindications to surgery, stenting or medical therapy may be preferable. In the absence of such concerns, and with functional independence and non-disabling TIA, timely carotid endarterectomy is the consensus recommendation. The current facts do NOT confirm the patient's surgical risk status, which may alter the first-line recommendation between endarterectomy and stenting or best medical therapy.
~~~~

### adversarial_correction_flip — turn 2 — FAIL

- Scenario turn: Correction: the patient is asymptomatic and the stenosis is 50–69%, not 70%.
- Expected guidelines: carotid_vertebral
- Routed guidelines: carotid_vertebral
- Evidence coverage: `interaction_gap`
- Retrieval returned 16 chunks: **YES**
- Judge labels: `missing_required_fact_correction_provenance`, `evidence_status_mismatch`
- Judge reason: The response correctly updates to asymptomatic 50–69% carotid stenosis and avoids prior erroneous details, but it does not retain or acknowledge the correction provenance as required. Additionally, the evidence_status reports an interaction_gap rather than the expected covered.

#### `guideline_grounded_answer` (verbatim)

~~~~text
According to ESVS guidelines, for patients with asymptomatic 50–69% carotid stenosis, there is no evidence supporting carotid intervention (endarterectomy or stenting) unless the patient is undergoing coronary artery bypass grafting (CABG) and a carotid intervention is deemed necessary in that specific context. For patients with asymptomatic 50–99% carotid stenosis not undergoing CABG, prophylactic carotid endarterectomy or stenting is not recommended. If they are scheduled for other major non-cardiac procedures, intervention is also not recommended. The guideline gives a specific recommendation class III (not recommended) for these situations.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
In the absence of symptoms and with a 50–69% degree of stenosis, best medical therapy remains standard care, and there is no ESVS-based indication for carotid intervention unless the patient is undergoing CABG and particular risk factors warrant consideration. No data supplied suggest this patient is scheduled for CABG or has modifying factors to alter pathway; thus, continue medical management. If new factors arise (e.g., planned CABG), revisit the carotid management as outlined.
~~~~

### adversarial_declined_question_persistence — turn 1 — FAIL

- Scenario turn: A patient has intermittent claudication and asks about management.
- Expected guidelines: asymptomatic_pad
- Routed guidelines: asymptomatic_pad
- Evidence coverage: `covered`
- Retrieval returned 12 chunks: **YES**
- Judge labels: `missing_expected_question`
- Judge reason: Did not ask the expected question about current smoking status in the initial case_new turn.

#### `guideline_grounded_answer` (verbatim)

~~~~text
According to ESVS guidelines, management of intermittent claudication should follow a stepwise approach:

- First-line: Offer risk factor management, best medical treatment, and a supervised exercise programme. This aims to improve maximum and pain-free walking distance, quality of life, and functional status. (Class I, Level A/B)
- Second-line: For patients with continued disabling symptoms despite compliant conservative management, consider revascularisation after a careful evaluation of disability degree, response to non-invasive treatment, comorbidities, procedural risk, and expected benefit. Engage the patient in shared decision-making about revascularisation options, weighing risks, potential benefits, and long-term patency. (Class I, Level C)
- After revascularisation, supervised exercise therapy should be initiated or continued to enhance walking capacity and quality of life, and reduce the likelihood of further procedures. (Class I, Level A)
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
The provided ESVS-based recommendations are well covered for typical cases of intermittent claudication. No additional high-impact uncertainties are present in this scenario, so a consultant could proceed confidently with the above management plan and appropriate patient discussion, including setting expectations and engaging in shared decision making if invasive treatments are considered. Further tailored questions (e.g., symptom severity, comorbidities, patient preferences) may become relevant after initial management if symptoms persist, but do not affect the current first-line recommendations.
~~~~

### adversarial_declined_question_persistence — turn 2 — PASS_WITH_MINOR

- Scenario turn: I decline to discuss smoking status. Please proceed with an explicit assumption.
- Expected guidelines: asymptomatic_pad
- Routed guidelines: asymptomatic_pad
- Evidence coverage: `interaction_gap`
- Retrieval returned 20 chunks: **YES**
- Judge labels: `mode_mismatch`
- Judge reason: The response acknowledged intermittent claudication, documented that smoking status was declined, and explicitly stated the operating assumption. It asked no further questions and routed to the expected guideline. However, it was delivered as a substantive follow-up rather than a gate reply as specified.

#### `guideline_grounded_answer` (verbatim)

~~~~text
For patients with intermittent claudication, ESVS guidelines recommend a stepwise approach: initial management should include risk factor management, best medical treatment, and exercise therapy. If symptoms remain lifestyle-limiting after adherence to these measures, agents such as cilostazol or naftidrofuryl oxalate may be considered, with reassessment after 3-6 months. Revascularisation may be considered for compliant patients with persistent disabling symptoms after noninvasive management, with all decisions individualized and involving shared decision making. Where supervised exercise therapy is not feasible, a structured home-based program with behavioral strategies is also recommended.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
Since smoking status is unknown and the patient declines to disclose, the stepwise management outlined in ESVS should still be followed. Smoking cessation would ordinarily form a major pillar of 'risk factor management,' but if the patient is not willing to discuss this, proceed with the remaining modifiable risk factors and documented guideline-based therapies. Explicitly document the assumption and continue standard care. If future information becomes available or the patient is willing to re-engage on this topic, readdress smoking cessation as appropriate.
~~~~

### adversarial_declined_question_persistence — turn 3 — FAIL

- Scenario turn: What should follow-up focus on?
- Expected guidelines: asymptomatic_pad
- Routed guidelines: asymptomatic_pad
- Evidence coverage: `interaction_gap`
- Retrieval returned 14 chunks: **YES**
- Judge labels: `missing_required_facts`, `assumption_not_recorded`, `did_not_acknowledge_decline`
- Judge reason: The response did not include the required acknowledgments that smoking status was declined and that an explicit assumption was recorded. While it addressed follow-up for intermittent claudication, stayed in the same case, and did not re-ask about smoking or pose new questions, it missed two must-include facts for this turn.

#### `guideline_grounded_answer` (verbatim)

~~~~text
According to ESVS, follow-up for patients with intermittent claudication should focus on: (1) monitoring risk factor management and adherence to best medical therapy (including statins), (2) ensuring continuation of and adherence to exercise therapy, and (3) regular assessment of walking distance, pain-free capacity, and symptoms. Revascularization is considered only if disabling symptoms persist despite these measures, and decisions should be individualized.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
Expert practice would translate ESVS to a structured follow-up: (1) Systematically review risk factors, medication adherence (particularly statins), and comorbidities at each visit; (2) actively inquire about changes in walking distance, pain-free walking, lifestyle limitation, and relief with rest; (3) promote/monitor participation in structured exercise; and (4) if symptoms worsen or become disabling, consider revascularization eligibility with shared decision-making. The interaction between these processes and optimal timing for referral is not directly governed by ESVS.
~~~~

### adversarial_duplicate_delivery — turn 1 — FAIL

- Scenario turn: Message-ID dup-001: CTA shows a 5.9 cm juxtarenal AAA.
- Expected guidelines: abdominal_aortic_aneurysm
- Routed guidelines: abdominal_aortic_aneurysm
- Evidence coverage: `covered`
- Retrieval returned 20 chunks: **YES**
- Judge labels: `mode_mismatch`, `same_case_incorrect`, `must_include_missing`, `idempotency_ack_missing`
- Judge reason: Turn expected mode case_new with same_case null, but system_output marked case_followup_substantive with same_case true. It included the 5.9 cm juxtarenal AAA fact but omitted the required acknowledgment 'message dup-001 merged once,' failing the idempotency/merge requirement. Therefore it misses a must-include fact and has mode/state mismatches.

#### `guideline_grounded_answer` (verbatim)

~~~~text
According to the ESVS 2024 Clinical Practice Guidelines, patients with complex abdominal aortic aneurysms (such as juxtarenal aneurysms) may be considered for elective repair at a diameter of 55 mm in men and 50 mm in women, taking into account fitness for repair, aneurysm anatomy, and patient preferences. In this case, the 5.9 cm (59 mm) juxtarenal aneurysm meets the threshold for consideration of elective repair in both men and women. The guidelines do not specify a mandatory repair but recommend individualized decision-making based on additional factors including patient preferences and suitability for repair.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
This patient’s aneurysm size exceeds both gender-based thresholds for consideration of repair (55 mm for men, 50 mm for women). The guidelines advise that for juxtarenal aneurysms—being 'complex'—the next key steps are: assessment of anatomical suitability for endovascular vs open repair, evaluation of the patient’s overall fitness for major intervention, and inclusion of the patient’s values and preferences. As the patient model already includes the necessary diameter and acknowledges the gender-specific repair thresholds, no additional discriminating unknowns remain at this decision level. If gender, fitness, or anatomical suitability were uncertain or missing, these would represent high-impact unknowns. In absence of such gaps and with evidence coverage complete, elective repair is guideline-supported but not mandatory. Technique selection (EVAR vs open) and specific perioperative risks require further clinical detail, typically addressed in multidisciplinary assessment.
~~~~

### adversarial_duplicate_delivery — turn 2 — FAIL

- Scenario turn: Message-ID dup-001: CTA shows a 5.9 cm juxtarenal AAA.
- Expected guidelines: abdominal_aortic_aneurysm
- Routed guidelines: abdominal_aortic_aneurysm
- Evidence coverage: `covered`
- Retrieval returned 10 chunks: **YES**
- Judge labels: `missing_must_include_facts`, `idempotency_state_not_acknowledged`
- Judge reason: Did not include the required acknowledgment that the duplicate message (dup-001) was merged once, a mandated must-include fact for this follow-up turn, though the 5.9 cm juxtarenal AAA fact and other constraints were met.

#### `guideline_grounded_answer` (verbatim)

~~~~text
According to ESVS guidelines, patients with complex abdominal aortic aneurysms (such as a juxtarenal AAA) may be considered for elective repair at a diameter of 55 mm in men and 50 mm in women, taking into account fitness for repair, aneurysm anatomy, and patient preferences. As the patient has a 5.9 cm (59 mm) juxtarenal AAA, this lesion exceeds the threshold for elective repair in both genders.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
The guideline directly supports considering elective repair for this patient's aneurysm, given its size is above threshold for both men and women. Further decisions regarding surgical technique (open versus endovascular), specific device suitability, and optimization of perioperative risk would require additional assessment of anatomical detail, comorbidities, and patient fitness—matters not included in the guideline text but standard to clinical decision-making. However, there are no branch-impacting unknowns raised by this question based on the current vignette; the threshold-based decision to consider repair is clear.
~~~~

### adversarial_knowledge_interleave — turn 1 — FAIL

- Scenario turn: A 72-year-old man has an asymptomatic 5.7 cm infrarenal AAA and CKD.
- Expected guidelines: abdominal_aortic_aneurysm
- Routed guidelines: abdominal_aortic_aneurysm
- Evidence coverage: `partial_principles`
- Retrieval returned 8 chunks: **YES**
- Judge labels: `contradicts_case_details`, `missing_required_facts`
- Judge reason: The response incorrectly refers to the AAA as symptomatic (contradicting the case’s asymptomatic status) and does not include all required case facts (omits the patient’s age/sex; does not clearly restate the 5.7 cm infrarenal detail in the grounded section).

#### `guideline_grounded_answer` (verbatim)

~~~~text
According to the ESVS 2024 Clinical Practice Guidelines:
- Men with an asymptomatic abdominal aortic aneurysm ≥ 55 mm (5.5 cm) should be considered for elective repair and fast-tracked for vascular surgical care.
- Prior to elective repair, assessment of pre-operative kidney function by measuring serum creatinine and estimated GFR is recommended, particularly important for those with renal impairment.
- Patients with renal impairment should be adequately hydrated before elective repair.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
While the ESVS guidelines support elective repair for this patient's 5.7 cm symptomatic infrarenal AAA and recommend pre-operative kidney function assessment plus hydration due to CKD, they do not specify further risk stratification, repair technique, or timing nuances that would be affected by the degree of kidney dysfunction or patient fitness. Fitness for surgery, precise anatomic suitability and multidisciplinary optimization (including nephrology input for advanced CKD) are critical, but not dictated by any snippet. In clinical reality, the specific approach (open vs EVAR) and timing are highly dependent on detailed imaging and functional/anaesthetic risk assessment, which are not directly resolved by current ESVS statements.
~~~~

### adversarial_knowledge_interleave — turn 2 — FAIL

- Scenario turn: As a general knowledge question, what diameter threshold does ESVS use in women?
- Expected guidelines: abdominal_aortic_aneurysm
- Routed guidelines: abdominal_aortic_aneurysm
- Evidence coverage: `covered`
- Retrieval returned 6 chunks: **YES**
- Judge labels: `MISSING_REQUIRED_FACTS`, `FORMATTING`
- Judge reason: The response did not include the required case facts (72-year-old man, asymptomatic 5.7 cm infrarenal AAA, CKD) despite same_case=true and must_include_facts. It also used heavy Markdown formatting (headings) contrary to instructions.

#### `guideline_grounded_answer` (verbatim)

~~~~text
ESVS recommends that women with an abdominal aortic aneurysm ≥ 50 mm may be considered for elective repair (Recommendation 23; Class IIb, Level C). Women with an asymptomatic AAA < 50 mm are not recommended for elective repair (Recommendation 21; Class III, Level C). For complex AAAs the guideline likewise cites thresholds of ≥ 55 mm in men and ≥ 50 mm in women (Recommendation 116; Class IIb, Level C).
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
In practice, the guideline treats 50 mm as the key diameter threshold for considering elective repair in women, with the decision tempered by fitness for surgery, aneurysm anatomy, and patient preferences. Thresholds are lower for women than for men (men: 55 mm) reflecting higher rupture risk and worse outcomes at smaller diameters in women; therefore individualized assessment around the 50 mm mark is common. This does not replace clinical judgment—factors such as aneurysm growth rate, symptoms, comorbidity, and anatomical suitability for open or endovascular repair influence timing.
~~~~

### adversarial_knowledge_interleave — turn 3 — FAIL

- Scenario turn: Back to this patient: renal function has worsened. How does that affect planning?
- Expected guidelines: abdominal_aortic_aneurysm
- Routed guidelines: abdominal_aortic_aneurysm
- Evidence coverage: `covered`
- Retrieval returned 6 chunks: **YES**
- Judge labels: `missing_required_case_facts`, `formatting_violation`
- Judge reason: The response did not explicitly include the required patient-specific facts (72-year-old man, asymptomatic 5.7 cm infrarenal AAA, CKD, and worsened renal function) as specified in must_include_facts. Additionally, it used heavy Markdown formatting (section headers) despite no request for such formatting.

#### `guideline_grounded_answer` (verbatim)

~~~~text
According to ESVS guidelines, worsened renal function in a patient planned for elective abdominal aortic aneurysm repair requires:
- Assessment of pre-operative kidney function by measuring serum creatinine and estimated glomerular filtration rate (eGFR), especially if eGFR is under 30 mL/min/1.73 m².
- Adequate pre-operative hydration.
- Referral to a nephrologist should be considered if severe renal impairment is present (eGFR < 30 mL/min/1.73 m²).
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
Worsened renal function elevates perioperative risk and mandates close attention to kidney protection strategies around operative planning. There is no specific guideline-based recommendation to alter the decision to treat based solely on renal function; rather, the guidance focuses on risk mitigation through optimal hydration, nephrology involvement in severe cases, and confirmation of stable/acceptable pre-operative renal status. The choice between open and endovascular approaches may be influenced by renal dysfunction, especially due to contrast use or clamp time, but this nuance is not directly addressed in the provided snippets and is not specified in this case.
~~~~

### adversarial_retrieval_trap — turn 1 — FAIL

- Scenario turn: A patient has an infrarenal abdominal aortic mural thrombus with distal embolisation. Which ESVS pathway should ground the assessment?
- Expected guidelines: abdominal_aortic_aneurysm
- Routed guidelines: abdominal_aortic_aneurysm
- Evidence coverage: `partial_principles`
- Retrieval returned 18 chunks: **YES**
- Judge labels: `guideline_key_mismatch`, `wrong_pathway_selection`, `retrieval_recovery_missing`
- Judge reason: The answer grounds the assessment in the Acute Limb Ischaemia (ALI) guideline instead of the expected ESVS abdominal aortic aneurysm pathway. It does include the required facts about infrarenal abdominal aortic mural thrombus and distal embolisation and avoids using the descending thoracic aorta as final grounding, but it fails the core routing requirement and does not demonstrate recovery from off-target retrieval as expected.

#### `guideline_grounded_answer` (verbatim)

~~~~text
The ESVS pathway for a patient with an infrarenal abdominal aortic mural thrombus and distal embolisation should be grounded in the acute limb ischaemia (ALI) guidelines. Specifically:
- The initial assessment should use the Rutherford classification of acute limb ischaemia to determine the clinical severity (e.g., sensory/motor loss, perfusion, duration).
- Urgency of intervention is determined by the Rutherford class: motor or sensory loss (Class IIb) indicates need for urgent transfer and revascularisation.
- Imaging for vascular assessment should use modalities such as CTA or duplex ultrasound, per guideline recommendations on evaluating the entire vascular tree and adjacent structures in ALI.

There is no direct ESVS pathway for mural aortic thrombus apart from ALI assessment and management principles if the patient presents with distal embolic sequelae.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
The main ESVS principles apply when mural thrombus causes symptomatic distal embolisation (i.e., acute limb ischaemia): assess with Rutherford classification, use high-quality vascular imaging (CTA/duplex), and determine urgency of intervention according to clinical presentation. Management specifics (technique, timing) may further depend on patient factors (e.g., time since embolisation, comorbidities, and imaging findings of the aorta and lower limbs), but are not directly defined for aortic mural thrombus in the ESVS. If the embolisation does not cause ischaemic symptoms, or if the mural thrombus is an incidental finding without ALI, ESVS guidance is lacking and expert opinion or multidisciplinary team review is required.
~~~~

### batch_c1_proximal_dvt_simple — turn 1 — PASS_WITH_MINOR

- Scenario turn: Patient with proximal femoral DVT, no severe symptoms, no cancer, no bleeding risk. Should this patient receive anticoagulation alone, undergo thrombolysis, or have an IVC filter?
- Expected guidelines: venous_thrombosis
- Routed guidelines: venous_thrombosis, antithrombotic_therapy
- Evidence coverage: `covered`
- Retrieval returned 20 chunks: **YES**
- Judge labels: `F5`
- Judge reason: Correctly recommends anticoagulation alone, no thrombolysis, and no IVC filter, but omits the explicit 3‑month DOAC duration. Also not presented in the expected compact style.

#### `guideline_grounded_answer` (verbatim)

~~~~text
In a patient with proximal femoral DVT, no severe symptoms, no cancer, and no bleeding risk, ESVS guidelines recommend therapeutic anticoagulation as the primary treatment. Direct oral anticoagulants are preferred over low molecular weight heparin or vitamin K antagonists for the principal treatment phase. Early thrombus removal (thrombolysis) is reserved for selected patients with symptomatic iliofemoral DVT and is not routinely recommended here. Temporary inferior vena cava (IVC) filters are only recommended if there is a contraindication to anticoagulation; routine use of IVC filters in anticoagulated patients is not recommended.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
No high-impact unknowns are present; guideline-based recommendations are sufficient to proceed. Proximal femoral DVT without severe symptoms or contraindications to anticoagulation should be managed with anticoagulation alone per current standards.
~~~~

### batch_c2_brachial_vein_compression — turn 1 — PASS_WITH_MINOR

- Scenario turn: Patient with tumor compressing the brachial vein. No thrombosis. Symptomatic swelling. Should he take anticoagulation?
- Expected guidelines: venous_thrombosis
- Routed guidelines: venous_thrombosis, antithrombotic_therapy
- Evidence coverage: `not_covered`
- Retrieval returned 51 chunks: **YES**
- Judge labels: `F5`, `F7`
- Judge reason: Core guidance is correct: no anticoagulation without confirmed thrombosis and monitor for DVT. However, it does not explicitly address managing the underlying compression (tumor) beyond symptom compression therapy, and the response is not in the requested COMPACT mode (uses headings and extended narrative).

#### `guideline_grounded_answer` (verbatim)

~~~~text
No ESVS guideline recommendation covers the use of anticoagulation for symptomatic venous compression by tumor in the absence of imaging evidence of thrombosis. All recommendations pertain to patients with confirmed thrombosis, use of anticoagulation after venous intervention, or specific procedural settings. There are no ESVS-supported indications for anticoagulation solely for vein compression and swelling without thrombosis.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
In the absence of thrombosis or a recommendation from the relevant ESVS guidelines, routine anticoagulation is not supported for cases of tumor-related venous compression presenting only with swelling. Management should focus first on symptom relief (e.g., compression therapy) and monitoring for progression to thrombosis. Anticoagulation might be considered only if additional patient-specific factors (e.g., marked risk of thrombosis) exist and bleeding risk is low, but this would be individual expert practice rather than guideline-based. Discussion with the MDT and/or haematology may be appropriate. Regular re-assessment for development of thrombosis is warranted.
~~~~

### batch_c3_carotid_near_occlusion_criteria — turn 1 — PASS_WITH_MINOR

- Scenario turn: Give the criteria of carotid near-occlusion.
- Expected guidelines: carotid_vertebral
- Routed guidelines: carotid_vertebral
- Evidence coverage: `not_covered`
- Retrieval returned 7 chunks: **YES**
- Judge labels: `F5`
- Judge reason: Core criteria are correctly included (definition, distal ICA collapse/reduced calibre, severe proximal stenosis, contralateral comparison) and no management branch is added. However, the response is not compact and contains extraneous details (modalities, duplex velocity nuances, implications) beyond the requested criteria.

#### `guideline_grounded_answer` (verbatim)

~~~~text

~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
Carotid near-occlusion is an imaging diagnosis of a very severe internal carotid artery (ICA) stenosis in which the lumen distal to the high-grade lesion is markedly reduced (‘collapsed’) and distal flow is diminished or delayed. Key practical criteria and features used in practice are:

- Severe proximal ICA stenosis with a markedly narrowed distal ICA calibre compared with the expected normal distal ICA or the contralateral ICA (visual ‘‘collapse’’ of the distal ICA).
- Asymmetry between ipsilateral and contralateral distal ICA diameters (the ipsilateral distal ICA is substantially smaller).
- Reduced contrast opacification and/or delayed filling of the distal ICA on angiographic studies (DSA, CTA, or contrast-enhanced MRA).
- On duplex ultrasound there are very low peak systolic and end-diastolic velocities distal to the stenosis and high-resistance or diminished waveform patterns; however, velocity criteria for routine stenosis grading are unreliable in near-occlusion.
- Two commonly described anatomic subtypes: near-occlusion with full collapse of the distal ICA (markedly thread-like) and near-occlusion without full collapse (distal lumen reduced but not thread-like).

Modalities for diagnosis: digital subtraction angiography (gold standard), CT angiography and contrast MRA are commonly used and can demonstrate distal calibre reduction and delayed filling; duplex ultrasound can suggest the diagnosis but may be misleading for percentage stenosis estimation.

Clinical implication (brief): near-occlusion is distinct from ordinary high-grade stenosis because the distal ICA is collapsed and haemodynamics are altered; diagnostic recognition relies on imaging pattern (distal calibre reduction and delayed/poor opacification) rather than standard percent-stenosis measurements alone.
~~~~

### batch_f1_clti_aps_warfarin — turn 1 — PASS_WITH_MINOR

- Scenario turn: Patient with CLTI undergoing infrainguinal bypass has antiphospholipid syndrome on warfarin. Should anticoagulation be bridged perioperatively, and should antiplatelet therapy be added postoperatively?
- Expected guidelines: clti, antithrombotic_therapy
- Routed guidelines: clti, antithrombotic_therapy
- Evidence coverage: `interaction_gap`
- Retrieval returned 32 chunks: **YES**
- Judge labels: `F7`
- Judge reason: Meets core expectations: cites guideline support for conduit/post-bypass strategies, identifies lack of APS-specific perioperative protocol, and notes that combined therapy is not automatic and depends on bleeding vs graft risk. Mentions individualized bridging with rationale but falls short of explicitly stating that high-risk APS is often bridged in practice, making that element under-emphasized.

#### `guideline_grounded_answer` (verbatim)

~~~~text
The ESVS guidelines provide the following relevant points: 1) Patients undergoing infrainguinal bypass with autologous vein may be considered for vitamin K antagonists (e.g., warfarin) if not at high risk of bleeding. 2) Patients undergoing infrainguinal bypass using either autologous vein or prosthetic conduit who are at high risk of bleeding may be considered for single antiplatelet therapy. 3) No guideline recommendation was found regarding perioperative bridging of anticoagulation in patients with antiphospholipid syndrome undergoing bypass, nor on the specific combination of anticoagulation and antiplatelet therapy in this population.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
There is an explicit ESVS evidence gap on the management of perioperative anticoagulation and the addition of antiplatelet therapy specifically in patients with antiphospholipid syndrome on warfarin undergoing infrainguinal bypass. High-risk thrombophilia such as antiphospholipid syndrome increases the risk of both thrombosis (indicating rationale for continuous anticoagulation/bridging) and perioperative bleeding. Bridging decisions are generally individualized in practice, weighing bleeding risk, thrombotic history, and details of the surgery. The guideline supports use of vitamin K antagonist or antiplatelet therapy depending on graft type and bleeding risk, but is silent on combinatorial and bridging approaches for this scenario. For antiplatelet therapy, the ESVS allows consideration in high-bleeding-risk patients, but does not mandate combination with anticoagulation.
~~~~

### batch_f2_clti_itp_after_bypass — turn 1 — FAIL

- Scenario turn: Post-op management of CLTI patient with ITP submitted to bypass surgery.
- Expected guidelines: clti, antithrombotic_therapy
- Routed guidelines: clti, antithrombotic_therapy
- Evidence coverage: `not_covered`
- Retrieval returned 11 chunks: **YES**
- Judge labels: `F2`, `F6`, `F7`
- Judge reason: The answer primarily highlights a guideline gap and defers to multidisciplinary input without providing the core expected management points. It fails to state the standard post-bypass regimen (aspirin plus low-dose rivaroxaban) contingent on acceptable bleeding risk, does not clearly articulate that ITP may place the patient outside the standard group, and does not propose a dynamic, platelet/bleeding-status–based approach with stepwise or delayed escalation. Although it asks relevant clarifying questions, it does not deliver the FULL, actionable guidance expected by the rubric.

#### `guideline_grounded_answer` (verbatim)

~~~~text
The ESVS guidelines do not provide specific recommendations for postoperative management or antithrombotic therapy in CLTI patients who have immune thrombocytopenia (ITP) following bypass surgery. Principles of limb staging, wound care, and general surveillance are mentioned, but there is a complete guidance gap regarding interacting bleeding disorders such as ITP.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
Due to the total absence of ESVS-specified management strategies for this dual pathology (CLTI + ITP), multidisciplinary input is essential. Key decisions—such as whether and which antithrombotic to prescribe—depend on haematology guidance about a safe platelet threshold and current management of the ITP. This must be established before vascular protocols can be followed. Surgical principles from the bypass (graft surveillance, limb and wound observation) still apply, but the presence of ITP demands individualized planning around bleeding and thrombosis. No ESVS guidance supports or opposes any particular strategy; proceed according to best practice, institutional protocols, and consensus with haematology.
~~~~

### batch_f3_aaa_clti_sequencing — turn 1 — PASS_WITH_MINOR

- Scenario turn: Patient with a 5.8 cm infrarenal AAA and concomitant CLTI (Rutherford 5, tissue loss). Which should be treated first — aneurysm repair or limb revascularisation? Clarifications: asymptomatic AAA, stable.
- Expected guidelines: abdominal_aortic_aneurysm, clti
- Routed guidelines: abdominal_aortic_aneurysm, clti
- Evidence coverage: `not_covered`
- Retrieval returned 58 chunks: **YES**
- Judge labels: `OMITTED_POINT_BOTH_CONDITIONS_COVERED`
- Judge reason: Meets key rubric points: states no ESVS sequencing rule; prioritizes limb revascularisation first given stable asymptomatic AAA; provides an explicit sequencing decision; includes required case facts. Minor omission: does not explicitly state that each condition is guideline-covered individually.

#### `guideline_grounded_answer` (verbatim)

~~~~text
The ESVS guidelines do not provide a recommendation regarding treatment sequencing or prioritization between asymptomatic, stable 5.8 cm infrarenal abdominal aortic aneurysm (AAA) and concomitant chronic limb-threatening ischemia (CLTI) Rutherford 5 with tissue loss. There is no covered guidance on which condition should be treated first—aneurysm repair or limb revascularisation—when both coexist without rupture or acute symptoms.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
In the absence of ESVS guidance, expert practice typically prioritizes the condition posing the most immediate threat to life or limb. Asymptomatic, stable 5.8 cm infrarenal AAAs have a lower immediate risk of rupture compared to the risk of limb loss from untreated Rutherford 5 CLTI with tissue loss. Therefore, it is generally reasonable to prioritize urgent limb revascularisation before addressing the asymptomatic AAA, unless the aneurysm is at very high risk for rupture, symptomatic, or rapidly expanding. Multidisciplinary decision-making, consideration of the patient's physiological reserve, anatomical constraints, and institutional expertise should inform the exact sequence, and sometimes combined (hybrid) approaches are individualized. In summary, in most such scenarios, limb threat takes precedence over a non-ruptured, stable AAA.
~~~~

### batch_f4_aaa_clti_sepsis_anticoagulation — turn 1 — PASS_WITH_MINOR

- Scenario turn: Patient with 6.5 cm infrarenal AAA and concomitant CLTI (Rutherford 6, wet gangrene with sepsis) on rivaroxaban for AF. Should you prioritise aneurysm repair, limb surgery, or infection control first? How should anticoagulation and antiplatelet therapy be managed perioperatively? Clarifications: AAA asymptomatic, stable.
- Expected guidelines: abdominal_aortic_aneurysm, clti, antithrombotic_therapy
- Routed guidelines: abdominal_aortic_aneurysm, clti, antithrombotic_therapy
- Evidence coverage: `not_covered`
- Retrieval returned 26 chunks: **YES**
- Judge labels: `F6`
- Judge reason: The answer correctly prioritizes infection/source control and implies limb surgery before AAA repair in a stable asymptomatic aneurysm, and it advises withholding rivaroxaban perioperatively. However, it is non-committal on bridging (does not clearly state no routine bridging for standard AF) and omits a clear restart criterion tied to haemostasis and infection control.

#### `guideline_grounded_answer` (verbatim)

~~~~text
No ESVS guideline—across abdominal aortic aneurysm, chronic limb-threatening ischaemia (Rutherford 6 with sepsis), or antithrombotic therapy domains—directly addresses the management priority (sequencing of aneurysm repair, limb surgery, and infection control) or the perioperative management of anticoagulation and antiplatelet therapy in this exact combination of asymptomatic, stable 6.5 cm AAA with acute limb sepsis and ongoing rivaroxaban therapy for atrial fibrillation. There are no path-specific or principle-based recommendations from ESVS covering this scenario.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
In the absence of ESVS guidance, senior vascular surgical practice would generally prioritize emergent infection control and source control (generally via amputation or surgical debridement) in a patient with wet gangrene and sepsis (Rutherford 6 CLTI), especially as the AAA is asymptomatic and stable. Delaying source control for elective aneurysm repair is risky due to the high short-term mortality of sepsis. The risk of AAA rupture—though not negligible at 6.5 cm—is typically judged lower than the immediate threat of severe sepsis from limb infection.

Regarding anticoagulation: for urgent surgery (such as amputation), rivaroxaban is generally withheld perioperatively due to bleeding risk, with careful balance of thromboembolic (AF-related) risk. Re-introduction and precise bridging (or not) would depend on surgical urgency, renal and hepatic function, and multidisciplinary input. The role of antiplatelet therapy, if any, would depend on the revascularization approach chosen later (not specified).
~~~~

### batch_f5_urgent_cea_af_recent_gi_bleed — turn 1 — FAIL

- Scenario turn: 75-year-old with TIA 2 days ago, 80% symptomatic carotid stenosis, AF on apixaban, recent upper GI bleed 7 days ago now stable. Proceed to urgent CEA or delay? How should apixaban and antiplatelet therapy be managed?
- Expected guidelines: carotid_vertebral, antithrombotic_therapy
- Routed guidelines: carotid_vertebral, antithrombotic_therapy
- Evidence coverage: `interaction_gap`
- Retrieval returned 45 chunks: **YES**
- Judge labels: `F2`, `F3`, `F6`, `F7`
- Judge reason: Misses multiple core expectations: does not clearly commit to urgent CEA within days; punts key decisions to MDT without concrete recommendations; omits explicit guidance to stop apixaban perioperatively without routine bridging for AF; lacks a clear, front‑loaded antiplatelet plan tailored to recent GI bleed; and fails to caution against triple therapy. Overall tone is non‑committal with excessive deferral, not meeting the requested decisive, full‑mode guidance.

#### `guideline_grounded_answer` (verbatim)

~~~~text
ESVS 2023 guidelines recommend urgent carotid endarterectomy (CEA) for recently symptomatic (within 6 months) 70–99% carotid stenosis, provided perioperative risk is acceptable. In patients with atrial fibrillation and ipsilateral 50–99% symptomatic stenosis, a comprehensive multidisciplinary team (MDT) review is recommended to determine whether urgent revascularisation or anticoagulation alone is appropriate. Perioperative antiplatelet (ideally aspirin ± clopidogrel) therapy should be considered, after imaging excludes intracranial haemorrhage, and local protocols should specify the regimen. For patients at high risk of GI bleeding (age >65, prior recent GI bleed), gastric protection with a PPI not interacting with clopidogrel (e.g., pantoprazole) is recommended if dual antiplatelet therapy is prescribed. Perioperative anticoagulation management (apixaban interruption/timing) should be tailored by MDT, balancing stroke and bleeding risks; no ESVS interaction guidance exists for this triple risk situation.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
There is no ESVS recommendation on timing of urgent CEA, perioperative management of apixaban, and antiplatelet therapy when recent GI bleed and AF coexist. Expert practice would be to refer this case for urgent MDT review with senior vascular, neurology/stroke, anaesthetic, and haematology input. Key factors are surgical/anaesthetic fitness and the individualised balance of risks: (a) Potential early benefit of CEA for secondary prevention in severe symptomatic stenosis is well-established, but perioperative risk may be unacceptably high with recent GI bleeding and anticoagulation. (b) Management of apixaban interruption—timing and bridging, if any—would be based on bleeding versus thrombotic risk and is not specified in ESVS guidelines; consensus is required. (c) If surgery proceeds, start antiplatelet therapy only after MDT decision and after imaging excludes intracranial/cerebral haemorrhage. (d) Given high GI bleeding risk, PPI cover is advised if DAPT is used, selecting a PPI without clopidogrel interaction. Do not proceed with urgent CEA without MDT consensus on risk balance. If surgery is deferred, strict stroke prevention measures and close monitoring for recurrent ischaemia or rebleeding are indicated.
~~~~

### batch_s1_asymptomatic_carotid_stenosis — turn 1 — PASS_WITH_MINOR

- Scenario turn: Patient with asymptomatic carotid stenosis 75%, age 72, on best medical therapy, no prior stroke/TIA, unilateral disease, CTA confirmed, low surgical risk. Should this patient undergo CEA, CAS, or medical therapy only?
- Expected guidelines: carotid_vertebral
- Routed guidelines: carotid_vertebral
- Evidence coverage: `interaction_gap`
- Retrieval returned 24 chunks: **YES**
- Judge labels: `F5`
- Judge reason: Provides the correct management (medical therapy only) and includes key case facts, but is indirect, emphasizes a guideline gap, and omits a concise statement about CAS contingencies or that CEA is only for selected high-risk-feature cases. Minor clarity/coverage issues rather than substantive clinical error.

#### `guideline_grounded_answer` (verbatim)

~~~~text
There is no directly applicable ESVS recommendation for carotid intervention (CEA or CAS) versus best medical therapy for an asymptomatic patient with 75% unilateral carotid stenosis, age 72, low surgical risk, not undergoing major non-cardiac surgery, and with no other special circumstances documented. The ESVS guideline specifically does not recommend prophylactic carotid endarterectomy or stenting in asymptomatic patients undergoing non-cardiac surgery. No guidance is provided for intervention in non-surgical settings without further risk stratification.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
Current ESVS snippets do not specify the management of asymptomatic carotid stenosis outside the non-cardiac surgery context, nor do they elaborate when carotid intervention should be considered based on high-risk clinical or imaging features in this intermediate scenario. In expert practice, the threshold for considering CEA in an asymptomatic patient with 75% stenosis and low surgical risk would depend critically on the presence of high-risk features (such as silent infarcts, contralateral occlusion, plaque ulceration, progression, or microemboli on TCD), but this is not explicit in the supplied guideline text. In the absence of documented high-risk features, the recommendation remains best medical therapy according to directly supported content.

If clinical or imaging high-risk stroke features were present, decision-making might diverge, but such pathways are currently not grounded in the explicit ESVS text provided.
~~~~

### batch_s2_post_vein_bypass_antithrombotics — turn 1 — FAIL

- Scenario turn: What is the recommended antithrombotic therapy after lower limb revascularization for peripheral arterial disease? Clarifications: vein BK bypass, rest pain pre-op, no high bleeding risk.
- Expected guidelines: clti, antithrombotic_therapy
- Routed guidelines: clti, antithrombotic_therapy
- Evidence coverage: `interaction_gap`
- Retrieval returned 19 chunks: **YES**
- Judge labels: `F1`, `F3`
- Judge reason: Misses the core recommendation to use aspirin 75–100 mg daily plus rivaroxaban 2.5 mg BID after infrainguinal vein bypass when bleeding risk is acceptable, and instead emphasizes vitamin K antagonists. Also omits guidance to avoid prolonged clopidogrel beyond 30 days. While it mentions single antiplatelet therapy for high bleeding risk, the primary regimen and clopidogrel duration advice are not provided and unrelated endovascular context is introduced.

#### `guideline_grounded_answer` (verbatim)

~~~~text
From the retrieved ESVS material: 1) All patients after revascularization should continue best medical therapy and long‑term antiplatelet therapy is a cornerstone to reduce atherothrombotic events. 2) For patients undergoing infrainguinal bypass with autologous vein who are NOT at high bleeding risk, vitamin K antagonists may be considered to improve graft patency (Recommendation 40; Class IIb, Level A). 3) Patients at high bleeding risk undergoing infrainguinal bypass may be considered for single antiplatelet therapy to improve graft patency (Recommendation 43; Class IIb, Level C). 4) For endovascular interventions (separate context) aspirin combined with low‑dose rivaroxaban is recommended to reduce cardiovascular and limb events (separate recommendation).
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
For a patient with a below‑knee autologous vein bypass for rest pain and no high bleeding risk, the guideline excerpts support considering therapeutic options to maximise graft patency: specifically, discussion of anticoagulation with a vitamin K antagonist as an option to improve vein‑graft patency is reasonable. Ensure continuation of best medical therapy (antiplatelet strategy and risk‑factor control). Practical steps: discuss VKA vs antiplatelet strategies with the vascular surgeon and patient, assess perioperative bleeding risk and monitoring logistics if VKA is chosen, and plan follow‑up surveillance of the graft. Individual patient factors (renal function, prior bleeding, need for dual therapy for other indications, ability to monitor VKA) will affect the final choice.
~~~~

### batch_s3_post_endovascular_antithrombotics_itp — turn 1 — PASS_WITH_MINOR

- Scenario turn: What is the recommended antithrombotic therapy after lower limb revascularization for peripheral arterial disease? Clarifications: endovascular tibial angioplasty DEB, symptomatic IC/CLTI, ITP.
- Expected guidelines: clti, antithrombotic_therapy
- Routed guidelines: clti, antithrombotic_therapy
- Evidence coverage: `interaction_gap`
- Retrieval returned 39 chunks: **YES**
- Judge labels: `F7`
- Judge reason: The answer correctly states standard post-endovascular options (short-course DAPT or aspirin plus low-dose rivaroxaban) and limits escalation to those without high bleeding risk. It acknowledges ITP as a bleeding-risk modifier and defaults to single antiplatelet therapy if high risk. However, it does not explicitly ask about platelet count/current bleeding status, and it does not clearly reference the DEB aspect of the tibial angioplasty in the core answer. Overall, it meets the core expectations but misses minor contextual and clarifying elements.

#### `guideline_grounded_answer` (verbatim)

~~~~text
According to ESVS, all patients after endovascular intervention for symptomatic lower extremity arterial disease (including intermittent claudication and CLTI) should receive single antiplatelet therapy. Dual antiplatelet therapy (aspirin plus clopidogrel for 1–6 months), or aspirin plus low-dose rivaroxaban, may be considered in patients who are not at high risk of bleeding. The guideline requires an assessment of bleeding risk before escalating antithrombotic therapy, but does not specify recommendations for patients with ITP or clarify at what degree of bleeding risk dual therapy should be withheld.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
There is an explicit guideline-driven branch: high-bleeding-risk patients (as many with ITP may be) should default to single antiplatelet therapy after tibial angioplasty. Escalation to dual antiplatelet therapy or aspirin + rivaroxaban is only for those NOT considered at high bleeding risk. The guidelines do not give detailed criteria for determining bleeding risk in the context of ITP, nor address the nuances if thrombocytopenia is labile or mild. Consultant practice typically involves discussion with hematology to formally assess bleeding risk before deviating from single agent therapy.
~~~~

### batch_s4_symptomatic_carotid_web — turn 1 — PASS_WITH_MINOR

- Scenario turn: How to treat symptomatic carotid web in a 40-year-old patient? Clarifications: symptoms 1 week ago, 70% stenosis, no prior history.
- Expected guidelines: carotid_vertebral
- Routed guidelines: carotid_vertebral
- Evidence coverage: `interaction_gap`
- Retrieval returned 19 chunks: **YES**
- Judge labels: `F7`
- Judge reason: Provides revascularization (CEA or CAS) and acknowledges limited evidence (Class IIb/Level C). However, it does not state the typical preference for CEA in a young, fit patient unless there are reasons to favor CAS, and it does not explicitly restate the case specifics (40-year-old, 70% stenosis, 1 week) in the recommendation.

#### `guideline_grounded_answer` (verbatim)

~~~~text
According to ESVS guidelines, for symptomatic patients with a carotid web in whom no other cause for stroke can be identified after detailed neurovascular work up, carotid endarterectomy or carotid artery stenting may be considered to prevent recurrent stroke (Class IIb, Level C). All elements except the outcome of a detailed neurovascular work up are verified in this patient. The guideline recommendation is conditional upon such work up confirming no alternative cause.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
In this scenario, strict ESVS application requires confirmation that a detailed neurovascular workup has excluded all other causes for stroke. If this exclusion has not yet been performed or is pending, it is premature to proceed to intervention based on guidelines. In practice, most vascular teams would await or prioritize rapid completion of this workup when considering CEA or CAS for a carotid web, particularly in a relatively young patient with otherwise low atherosclerotic risk. If the workup confirms no alternative etiology, then CEA or CAS are reasonable options, timed ideally within two weeks of symptoms per general principles for symptomatic stenosis.
~~~~

### batch_s5_iliofemoral_dvt_recent_surgery — turn 1 — PASS_WITH_MINOR

- Scenario turn: Patient with acute iliofemoral DVT extending into the common femoral vein, severe swelling and pain (phlegmasia alba), recent major abdominal surgery 5 days ago. Stable Hb, no phlegmasia cerulea, no other contraindications. Should this patient receive anticoagulation alone, catheter-directed thrombolysis, or surgical thrombectomy? How should bleeding risk influence the decision?
- Expected guidelines: venous_thrombosis
- Routed guidelines: venous_thrombosis, antithrombotic_therapy
- Evidence coverage: `interaction_gap`
- Retrieval returned 11 chunks: **YES**
- Judge labels: `F7`
- Judge reason: Correctly prioritizes anticoagulation and de-emphasizes thrombolysis/thrombectomy given recent surgery and no limb threat, and integrates bleeding-risk reasoning. However, it omits the contingency that an IVC filter is only considered if anticoagulation is not possible.

#### `guideline_grounded_answer` (verbatim)

~~~~text
Therapeutic anticoagulation (prefer DOACs over LMWH/VKA) is the class I recommendation in all cases unless bleeding risk is extremely high or active bleeding precludes anticoagulation. Early thrombus removal strategies (catheter-directed thrombolysis or surgical thrombectomy) may be considered (Class IIa A) only in selected patients with symptomatic iliofemoral DVT, allowing for severity of symptoms and bleeding risk. Major recent surgery is a bleeding risk factor, limiting the use of invasive or thrombolytic techniques; ESVS specifically notes that early thrombus removal should only be considered when bleeding risk is not unacceptably high.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
The guidelines do not provide a threshold for 'acceptable' bleeding risk or a post-surgical interval after which early thrombus removal becomes justifiable. In typical surgical practice, most major abdominal operations within 14 days (especially if ongoing haemostasis concerns exist) would be considered high risk for thrombolysis or invasive intervention. Unless the abdominal surgery was minor and there is unequivocal surgical reassurance regarding haemostasis, most experts would default to anticoagulation alone at this stage postoperatively. Only if bleeding risk has clearly resolved (no evidence of ongoing bleeding, stable surgical site) might intervention be reassessed. In phlegmasia alba, the bar for intervention is lower than in cerulea dolens, but clinical trajectory and evolving bleeding status are determinative.
~~~~

### batch_s6_urgent_cea_af_apixaban — turn 1 — FAIL

- Scenario turn: Patient with symptomatic carotid stenosis (80%) scheduled for urgent CEA is found to have AF on apixaban. Recent TIA 10 days ago. Persistent AF. How should anticoagulation be managed perioperatively, and should antiplatelet therapy be added?
- Expected guidelines: carotid_vertebral, antithrombotic_therapy
- Routed guidelines: carotid_vertebral, antithrombotic_therapy
- Evidence coverage: `interaction_gap`
- Retrieval returned 47 chunks: **YES**
- Judge labels: `F2`, `F3`, `F7`
- Judge reason: Does not affirm the urgency of CEA as expected and defers decisively to MDT, omits the explicit recommendation to stop DOAC perioperatively without routine bridging, and suggests long-term combined antiplatelet plus anticoagulation rather than avoiding prolonged combination strategies. These conflict with the core expectations and introduce potentially unsafe guidance.

#### `guideline_grounded_answer` (verbatim)

~~~~text
For patients with symptomatic 80% carotid stenosis and recent TIA scheduled for urgent carotid endarterectomy (CEA), ESVS recommends that antiplatelet therapy should be prescribed throughout the peri-operative period and long-term. Perioperative combination (dual) antiplatelet therapy may be considered after imaging has excluded intracranial haemorrhage. In patients with both symptomatic carotid stenosis and atrial fibrillation (AF), a comprehensive neurovascular multidisciplinary team (MDT) review is recommended to determine whether urgent carotid revascularisation plus anticoagulation or anticoagulation alone is indicated. There is no RCT or direct ESVS recommendation regarding the management of oral anticoagulation (e.g., apixaban) perioperatively when performing urgent CEA on patients with AF; MDT guidance and local protocols are recommended for balancing bleeding and thromboembolic risk.
~~~~

#### `interpretive_frame` (verbatim)

~~~~text
Non-ESVS interpretation (clinical reasoning beyond the retrieved guideline text):
There is an acknowledged interaction gap in ESVS guidance between antiplatelet and anticoagulant management in this specific scenario. While antiplatelet therapy is clearly recommended around CEA, and anticoagulation is required for AF, there is no explicit ESVS-endorsed regime for their combination in the perioperative period. Accepted practice often involves stopping direct oral anticoagulants before surgery to minimize perioperative bleeding risk, but this is a local decision requiring MDT discussion, particularly given the recent TIA. The addition of antiplatelet therapy is indicated, but concurrent full anticoagulation should not be continued perioperatively without MDT consensus. Long-term, both antiplatelet and anticoagulant therapy are indicated, but must be weighed against bleeding risk. MDT review is imperative both for decision on urgency of carotid revascularisation versus anticoagulation alone, and for perioperative plan.
~~~~
